All Categories
    Filters
    Preferences
    Search
    Brand: Septodont

    Septodont Scandonest® 3% Plain - Mepivacaine HCl 3% without Vasoconstrictor, 50x1.7ml Carp/Box

    Login For Price
    The product contains 3% Plain - Mepivacaine HCl 3% without Vasoconstrictor.

    Indications:

    • Local dental anesthesia by infiltration or nerve block in adults and pediatric patients

    Key Features:

    • Formulation without vaso-constrictor for specific medical situations.
    • Fast onset: 30 to 120 seconds in the maxilla and 1 to 4 minutes for the mandible.
    • Duration: will ordinarily provide pulpal anesthesia of about 20 minutes in the maxilla, and about 40 minutes in the mandible.
    • No-methylparaben formulation to avoid allergic reactions on sensitive patients.
    • 100 percent latex free components to help reduce allergic responses.
    • Terminal sterilization of product/cartridges for safe use.
    • Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage.
    • Cartridges packed 10 to a blister tray to avoid glass to glass contact, hence reducing breakage.

    Presentation:

    • Box containing 5 blisters of 10 x 1.7ml glass cartridges

    Risk:

    • Reactions to Scandonest® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Scandonest® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Scandonest® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

    Package contains:

    • 50 cartridges – A box of 5 blisters of 10 x 1.7 ml glass cartridges
    Part number: 211299203
    Customers who bought this item also bought

    Ultracaine® D-S Regular Articaine HCI 4% w/ 1:200,000 Epi (Green), 100x1.7ml Carp/Bx

    Ultracaine® is the world's original articaine and is exclusively available through HANSAmed. Cartridges have latex-free closures and recyclable all-cardboard packaging.

    Ultracaine® is the world’s original articaine and one of HANSAmed’s key products. It is available as an injectable local anesthetic and has been sold exclusively in Canada through HANSAmed since 1999.

    Ultracaine D-S contains 4% articaine hydrochloride (40 mg/mL) with 1:200,000 epinephrine (0.006 mg/mL epinephrine hydrochloride, which corresponds to 0.005 mg/mL epinephrine as a free base), sodium metabisulphite (0.50 mg/mL) as antioxidant, and water for injection.

    User Benefits

    • Epinephrine: 1:200,000 straight epinephrine
    • Pulpal Anesthesia: Provides 45-60 minutes of safe and effective pulpal anesthesia
    • Soft Tissue Anesthesia: Provides 120-300 minutes of safe and effective soft tissue anesthesia
    • Onset: 2-3 minutes onset
    • Half Life: 27 minutes half-life

    Indications & Clinical Use

    • Ultracaine D-S (articaine with epinephrine) solutions for injection are indicated for infiltration anesthesia and nerve block anesthesia in clinical dentistry.
    • Geriatrics (>65 years of age): elderly patients should be given reduced doses commensurate with their age and physical condition.
    • Pediatrics (<4 years of age): the use of Ultracaine D-S and Ultracaine D-S Forte (articaine with epinephrine solutions) in children under the age of 4 years is not recommended.

    Package contains:

    • 100 x 1.7mL carpule of Ultracaine® D-S Regular Articaine HCI 4% w/ 1:200,000 Epi (Green)

    Cook-Waite Lidocaine HCl 2% w/ Epi 1:100,000, (Red) 50 1.7ml Carp/Bx

    The product contains 2% Lidocaine HCl injection with 1:100,000 epinephrine bitartrate. This is a versatile local anesthetic of intermediate duration

    Indications:

    • Local dental anesthesia by nerve block or infiltration

    Key Features:

    • Lidocaine when used for infiltration will have an average onset time of less than two minutes and a duration of about 60 minutes. When used for nerve blocks the average onset time is 2 to 4 minutes and will provide about 90 minutes of pulpal anesthesia.
    • No-methylparaben formulation to avoid allergic reactions on sensitive patients.
    • 100 percent latex free components to help reduce allergic responses.
    • Terminal sterilization of product/cartridges for safe use.
    • Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage.
    • Cartridges packed 10 to a blister tray to avoid glass to glass contact, hence reducing breakage.

    Risk information:

    • Reactions to Lidocaine are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Lidocaine is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of lidocaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Lidocaine contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

    Package contains:

    • 50 cartridges – A box of 5 blisters of 10 x 1.7 ml glass cartridges

    Ultracaine® D-S Forte Articaine HCI 4% w/ 1:100,000 Epi (Blue), 100x1.7ml Carp/Bx

    Ultracaine® is the world’s original articaine and is exclusively available through HANSAmed. Cartridges with latex-free closures and recyclable all-cardboard packaging.

    Ultracaine® is the world’s original articaine and one of HANSAmed’s key products. It is available as an injectable local anesthetic and has been sold exclusively in Canada through HANSAmed since 1999.

    Ultracaine D-S Forte contains 4% articaine hydrochloride (40 mg/mL) with 1:100,000 epinephrine (0.006 mg/mL epinephrine hydrochloride, which corresponds to 0.005 mg/mL (epinephrine as a free base), sodium metabisulphite (0.50 mg/mL) as antioxidant, and water for injection.

    User Benefits

    • Epinephrine: 1:100,000 straight epinephrine; Ultracaine® D-S Forte is a longer lasting anesthetic than Ultracaine® D-S due to the higher concentration of epinephrine
    • Pulpal Anesthesia: Provides 60-75 minutes of safe and effective pulpal anesthesia
    • Soft Tissue Anesthesia: Provides 180-360 minutes of safe and effective soft tissue anesthesia
    • Onset: 1-2 minute infiltration; 2-3 minutes block
    • Half Life: 27 minutes half-life

    Indications & Clinical Use

    • Ultracaine D-S (articaine with epinephrine) solutions for injection are indicated for Infiltration anesthesia and nerve block anesthesia in clinical dentistry.
    • Geriatrics (>65 years of age): elderly patients should be given reduced doses commensurate with their age and physical condition.
    • Pediatrics (<4 years of age): the use of Ultracaine D-S and Ultracaine D-S Forte (articaine with epinephrine solutions) in children under the age of 4 years is not recommended.

    Package contains:

    • 100 x 1.7mL carpules of Ultracaine® D-S Forte Articaine HCI 4% w/ 1:100,000 Epi (Blue)

    Septodont Vivacaine® Bupivacaine HCl. 0.5 % and Epi 1:200,000 Inj, USP, 50x1.7ml Carp/Bx

    The product contains Bupivacaine HCl. 0.5 % and Epi 1:200,000. It is ideal for infiltration or nerve block injections in adults.

    Indications:

    • Local dental anesthesia by infiltration or nerve block injections in adults

    Key Features:

    • Anesthesia may last two to three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours.
    • Onset of action is usually 2 to 10 minutes.
    • No-methylparaben formulation to avoid allergic reactions on sensitive patients.
    • 100 percent latex free components to help reduce allergic responses.
    • Terminal sterilization of product/cartridges for safe use.
    • Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage.
    • Cartridges packed 10 to a blister tray to avoid glass to glass contact, hence reducing breakage.

    Presentation:

    • Box containing 5 blisters of 10 x 1.7ml glass cartridges

    Risk:

    • Reactions to Vivacaine® are characteristic of those used with other amide-type local anesthetics. A major cause of reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Vivacaine® is contraindicated in patients with a known hypersensitivity to it or any local anesthetic agent of the amide type or to other components of Vivacaine® solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, an the personnel resources needed for proper management of toxic reactions and related emergencies. Vivacaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please seen the Package Insert for prescribing information.

    Package contains:

    • 50 cartridges – A box of 5 blisters of 10 x 1.7 ml glass cartridges
    *
    *
    *